Clinical Significance and Prognostic Value of CA72-4 Compared with CEA and CA19-9 in Patients with Gastric Cancer

Por Ychou, M., Duffour, J., Kramar, A., Gourgou, S., Grenier, J.
Publicado em 2000

Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model

Por Leconte, A, Garambois, V, Ychou, M, Robert, B, Pourquier, D, Terskikh, A, Mach, J P, Pèlegrin, A
Publicado em 1999

p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis

Por Lopez-Crapez, E, Bibeau, F, Thézenas, S, Ychou, M, Simony-Lafontaine, J, Thirion, A, Azria, D, Grenier, J, Senesse, P
Publicado em 2005

Conservative surgery for low rectal carcinoma after high-dose radiation. Functional and oncologic results.

Por Rouanet, P, Fabre, J M, Dubois, J B, Dravet, F, Saint Aubert, B, Pradel, J, Ychou, M, Solassol, C, Pujol, H
Publicado em 1995

Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer

Por Azria, D, Larbouret, C, Garambois, V, Kramar, A, Martineau, P, Robert, B, Aillères, N, Ychou, M, Dubois, J B, Pèlegrin, A
Publicado em 2003

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

Por Conroy, T, Hebbar, M, Bennouna, J, Ducreux, M, Ychou, M, Llédo, G, Adenis, A, Faroux, R, Rebischung, C, Kockler, L, Douillard, J Y
Publicado em 2010

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer

Por Conroy, T, Viret, F, François, E, Seitz, J F, Boige, V, Ducreux, M, Ychou, M, Metges, J P, Giovannini, M, Yataghene, Y, Peiffert, D
Publicado em 2008

PD-012 Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC)

Por Van Cutsem, E., Ciardiello, F., Ychou, M., Seitz, J.-F., Hofheinz, R., Arriaga, Y., Garcia-Carbonero, R., Grothey, A., Miriyala, A., Kalmus, J., Kappeler, C., Falcone, A., Zaniboni, A.
Publicado no Ann Oncol (2016)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

Por Oden-Gangloff, A, Di Fiore, F, Bibeau, F, Lamy, A, Bougeard, G, Charbonnier, F, Blanchard, F, Tougeron, D, Ychou, M, Boissière, F, Le Pessot, F, Sabourin, J-C, Tuech, J-J, Michel, P, Frebourg, T
Publicado em 2009

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

Por Samalin, E, Bouché, O, Thézenas, S, Francois, E, Adenis, A, Bennouna, J, Taieb, J, Desseigne, F, Seitz, J F, Conroy, T, Galais, M P, Assenat, E, Crapez, E, Poujol, S, Bibeau, F, Boissière, F, Laurent-Puig, P, Ychou, M, Mazard, T
Publicado em 2014